Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 <sup>+</sup> effector memory T‐cells
David Eastwood(University of Hertfordshire), Richard Stebbings(AstraZeneca (United Kingdom))
Cited by 290
Related Papers
Characterization of a novel potency endpoint for the evaluation of immune checkpoint blockade in humanized mice
|Frontiers in Immunology|2023|2